DCT

3:24-cv-09017

Rayner Surgical Inc v. Somerset Therap LLC

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: Rayner Surgical Inc. v. Somerset Therapeutics, LLC, 3:24-cv-09017, D.N.J., 09/06/2024
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Somerset has a regular and established place of business in New Jersey and has committed acts of infringement within the district.
  • Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's OMIDRIA® ophthalmic solution constitutes an act of infringement of three U.S. patents.
  • Technical Context: The technology concerns stable, preservative-free, and antioxidant-free injectable solutions containing a mydriatic (phenylephrine) and an anti-inflammatory (ketorolac) for use during cataract surgery.
  • Key Procedural History: This patent infringement action was initiated under the Hatch-Waxman Act following Defendant's submission of ANDA No. 219384 with a Paragraph IV certification, asserting that Plaintiff's patents are invalid, unenforceable, or will not be infringed. The patents-in-suit are listed in the FDA's "Orange Book" for Plaintiff's OMIDRIA® product. The complaint notes that at the time of filing, Plaintiffs had not received access to the Somerset ANDA, citing unreasonable restrictions proposed by Somerset.

Case Timeline

Date Event
2012-10-24 Earliest Priority Date for '856, '406, and '246 Patents
2014-05-01 FDA Approval of OMIDRIA® New Drug Application
2015-06-30 U.S. Patent No. 9,066,856 Issued
2016-11-08 U.S. Patent No. 9,486,406 Issued
2018-01-02 U.S. Patent No. 9,855,246 Issued
2024-07-26 Defendant sends Paragraph IV Notice Letter to Plaintiffs
2024-09-06 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,066,856 - "Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection"

  • Patent Identification: U.S. Patent No. 9,066,856, "Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection," issued June 30, 2015. Compl. ¶24

The Invention Explained

  • Problem Addressed: The patent background describes the need for solutions to maintain pupil dilation (mydriasis) and reduce pain during ophthalmic surgery Compl. ¶18 It notes that commonly used agents like epinephrine, when included in irrigation solutions, often contain preservatives or antioxidants (e.g., sodium metabisulfite) that have been associated with potential toxicity to ocular tissues, such as Toxic Anterior Segment Syndrome (TASS) '856 Patent, col. 2:1-12
  • The Patented Solution: The invention is a stable liquid pharmaceutical formulation that combines a mydriatic agent (phenylephrine) and an anti-inflammatory agent (ketorolac) in a buffered aqueous solution that is explicitly free of preservatives and antioxidants '856 Patent, abstract This formulation is designed to provide the necessary surgical effects while avoiding the potential toxicity of additives, yet remain stable for an extended period '856 Patent, col. 3:45-53
  • Technical Importance: The technology provided a means to combine two therapeutically useful agents for ophthalmic surgery into a single, stable formulation without the need for potentially toxic preservatives or antioxidants. Compl. ¶20

Key Claims at a Glance

  • The complaint asserts infringement of at least Claim 1 Compl. ¶38
  • Independent Claim 1 Elements:
    • A sterile liquid pharmaceutical formulation
    • consisting essentially of phenylephrine, ketorolac and a buffer system in an aqueous carrier,
    • wherein the formulation is stable for at least six months
    • when stored at a temperature of from 5+/-3° C. to 25 +/-2° C.

U.S. Patent No. 9,486,406 - "Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection"

  • Patent Identification: U.S. Patent No. 9,486,406, "Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection," issued November 8, 2016. Compl. ¶25

The Invention Explained

  • Problem Addressed: The patent addresses the same technical problem as the '856 Patent: the need for a stable, injectable ophthalmic solution for surgery that avoids potentially toxic preservatives and antioxidants '406 Patent, col. 1:49 - col. 2:24
  • The Patented Solution: The '406 Patent describes a liquid pharmaceutical formulation containing phenylephrine and ketorolac in a buffered aqueous carrier that achieves long-term stability "without the inclusion of preservatives and antioxidants" '406 Patent, claim 2 This claim structure, with its explicit negative limitation, distinguishes it from the "consisting essentially of" language in the '856 Patent.
  • Technical Importance: As with the parent '856 Patent, this technology provides a dual-action ophthalmic solution that enhances safety by eliminating potentially harmful additives while maintaining chemical stability. Compl. ¶20

Key Claims at a Glance

  • The complaint asserts infringement of at least Claim 2 Compl. ¶57
  • Independent Claim 2 Elements:
    • A liquid pharmaceutical formulation
    • comprising phenylephrine, ketorolac and a buffer system in an aqueous carrier,
    • wherein the formulation is stable without the inclusion of preservatives and antioxidants for at least six months
    • when stored at a temperature of from 5+/-3°C. to 25+/-2° C.

U.S. Patent No. 9,855,246 - "Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection"

  • Patent Identification: U.S. Patent No. 9,855,246, "Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection," issued January 2, 2018. Compl. ¶26

Technology Synopsis

This patent, part of the same family, claims a liquid intraocular ophthalmic solution containing phenylephrine and ketorolac that is free of preservatives, antioxidants, and solubilizing agents '246 Patent, abstract A key feature of the asserted claim is the requirement that the solution be in a single-use container with a "nitrogen gas overlay," a manufacturing step intended to further enhance stability by displacing oxygen '246 Patent, claim 1

Asserted Claims

The complaint asserts infringement of at least Claim 1 Compl. ¶76

Accused Features

The complaint alleges on information and belief that the Defendant's ANDA product is a liquid solution dosage form with the claimed components and concentrations, free of the excluded agents, and packaged in a single-use container with a nitrogen gas overlay. Compl. ¶77

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Somerset's proposed generic version of OMIDRIA®, identified as the "ANDA Product" in the complaint Compl. ¶1 It is described as a "ketorolac tromethamine, phenylephrine hydrochloride solution" Compl. ¶27

Functionality and Market Context

  • The ANDA Product is a sterile liquid pharmaceutical formulation intended for use during cataract surgery or intraocular lens replacement Compl. ¶18 Its alleged function is to maintain pupil size by preventing miosis and to reduce postoperative pain, mirroring the indications for OMIDRIA® Compl. ¶18
  • The complaint alleges that Somerset seeks to manufacture and market this product as a generic equivalent to OMIDRIA® prior to the expiration of the patents-in-suit Compl. ¶1 Compl. ¶28 The legal action is based on the submission of ANDA No. 219384 to the FDA, which is a statutory act of infringement Compl. ¶1
  • No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

9,066,856 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A sterile liquid pharmaceutical formulation Somerset's ANDA product is alleged to be a sterile liquid pharmaceutical formulation. ¶39 col. 3:45-48
consisting essentially of phenylephrine, ketorolac and a buffer system in an aqueous carrier, The ANDA product is alleged to consist essentially of phenylephrine, ketorolac, and a buffer system in an aqueous carrier, based on FDA regulations requiring generic ophthalmic drugs to contain the same inactive ingredients as the reference drug. ¶39; ¶37 col. 7:51-57
wherein the formulation is stable for at least six months when stored at a temperature of from 5+/-3° C. to 25 +/-2° C. The complaint alleges that Somerset's Notice Letter does not dispute that its formulation meets the stability requirement. ¶39 col. 8:19-30

9,486,406 Infringement Allegations

Claim Element (from Independent Claim 2) Alleged Infringing Functionality Complaint Citation Patent Citation
A liquid pharmaceutical formulation comprising phenylephrine, ketorolac and a buffer system in an aqueous carrier, Somerset's ANDA product is alleged to be a liquid pharmaceutical formulation containing these components. ¶58 col. 3:52-54
wherein the formulation is stable without the inclusion of preservatives and antioxidants for at least six months The ANDA product is alleged to be a formulation that achieves stability without the inclusion of preservatives and antioxidants. ¶58 col. 4:28-31
when stored at a temperature of from 5+/-3°C. to 25+/-2° C. The complaint states that Somerset's Notice Letter does not dispute that the formulation meets the stability requirement. ¶58 col. 4:31-34
  • Identified Points of Contention:
    • Factual Scope: A primary question will be the actual composition of the ANDA Product. The complaint is based on "information and belief" and regulatory requirements for bioequivalence Compl. ¶37 Compl. ¶56 The infringement analysis will depend entirely on the specific ingredients revealed in the ANDA filing.
    • Definitional Scope: For the '856 Patent, the term "consisting essentially of" raises the question of whether any unlisted ingredients in the ANDA Product "materially affect the basic and novel properties" of the invention-namely, its stability without traditional preservatives or antioxidants. For the '406 Patent, the infringement question may turn on whether any ingredient in the ANDA product, regardless of its primary purpose, could be defined as a "preservative" or "antioxidant."
    • Technical Questions: A key technical question is whether the ANDA product achieves the claimed stability. While the complaint alleges this is not in dispute based on the Notice Letter Compl. ¶39 Compl. ¶58, the underlying stability data from the ANDA will be critical evidence.

V. Key Claim Terms for Construction

  • The Term: "consisting essentially of" (from Claim 1 of the '856 Patent)

  • Context and Importance: This transitional phrase is narrower than "comprising" but broader than "consisting of." Its construction will determine whether the presence of any additional, unlisted ingredients in Defendant's formulation avoids infringement. The dispute will likely focus on whether any such ingredients materially affect the invention's "basic and novel properties"-the ability to achieve stability without traditional preservatives and antioxidants.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification discloses using sodium hydroxide and/or hydrochloric acid for pH adjustment, suggesting that the claims permit minor, unrecited components that do not alter the fundamental character of the invention '856 Patent, col. 9:18-20
    • Evidence for a Narrower Interpretation: The patent emphasizes its purity, stating that preferred formulations "consist essentially of the two APIs and the buffering system in water for injection" and that this yields "a very pure formulation with reduced potential for toxicity" '856 Patent, col. 9:44-49 A party could argue this shows an intent to exclude almost all other additives.

  • The Term: "without the inclusion of preservatives and antioxidants" (from Claim 2 of the '406 Patent)

  • Context and Importance: This negative limitation is central to the infringement analysis for the '406 Patent. Its scope will determine whether a component included for a different primary purpose (e.g., as a buffer or chelating agent) that also possesses some antioxidant properties would fall within the exclusion.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation (of the exclusion): The background explicitly criticizes even "preservative-free" solutions that still contain antioxidants like sodium metabisulfite, suggesting a strict intent to exclude any substance with antioxidant functionality, regardless of purpose '406 Patent, col. 2:5-12
    • Evidence for a Narrower Interpretation (of the exclusion): The patent defines an "antioxidant-free" solution as one that "does not include sodium metabisulfite or other agent that has been included for the sole function of serving as an antioxidant," but notes it may include a pH buffering system, like citric acid, which has antioxidant properties '406 Patent, col. 8:31-39 This provides a strong basis to argue that substances with incidental antioxidant properties are not excluded if their primary purpose is otherwise.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon FDA approval, Somerset will actively induce infringement by marketing the ANDA Product and providing prescribing information and product inserts that instruct healthcare professionals to use the product in an infringing manner Compl. ¶41 Compl. ¶60 Compl. ¶79
  • Willful Infringement: The complaint alleges that Somerset had "actual and constructive notice" of the patents-in-suit prior to filing its ANDA Compl. ¶42 Compl. ¶61 Compl. ¶80 It further alleges that Somerset filed its ANDA "without adequate justification for asserting the... Patent to be invalid, unenforceable, and/or not infringed," which it contends renders the case "exceptional" under 35 U.S.C. § 285 Compl. ¶43 Compl. ¶62 Compl. ¶81

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of definitional scope: can the term "antioxidant" in the '406 patent be construed to cover a substance, such as a chelating agent within a buffer, that has incidental antioxidant properties but is included for a different primary function? The patent's own specification provides conflicting signals that will be central to claim construction.
  • A second key issue will be the scope of the transition: for the '856 patent, does the phrase "consisting essentially of" permit the inclusion of any unrecited substance in the accused product, and if so, does that substance materially alter the formulation's stability, which the patent identifies as a basic and novel property?
  • A dispositive evidentiary question will be one of compositional fact: what is the exact formulation of the accused ANDA product? The entire infringement analysis depends on a comparison of that undisclosed formulation against the constructed claims, particularly with respect to the presence and function of any ingredients other than phenylephrine, ketorolac, a buffer, and water.
Loading Complaint